In pursuant to Notice of Board meeting dated 5th November 2025 the Board Meeting of the Company was held today Wednesday 12th November 2025 at 3.00 p.m. at 4th Floor, Sambava Chambers, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Triochem Products' board, meeting on 12th November 2025, approved its unaudited standalone financial results for Q2 and H1 FY26 (ended 30th September 2025), with auditors Kanu Doshi Associates LLP issuing an unqualified review report. Revenue from operations came in at ₹29.52 lakhs for Q2 (up from ₹26.69 lakhs YoY) and ₹51.62 lakhs for H1 (vs ₹49.66 lakhs). However, the company reported a net loss of ₹19.26 lakhs in Q2 and ₹22.32 lakhs in H1, widening from ₹3.66 lakhs and ₹11.50 lakhs respectively a year ago, with EPS of ₹(7.86) for Q2. Operating cash flow turned sharply negative at ₹(47.25) lakhs in H1 FY26 versus a positive ₹33.34 lakhs in H1 FY25, and cash balances fell to ₹52.25 lakhs from ₹90.66 lakhs. Notably, the board disclosed a proposed sale of immovable property, plant & machinery and investment property in Maharashtra as a Material Related Party Transaction — assets with a written-down value of just ₹56.92 lakhs but a fair market value of approximately ₹1,181 lakhs (₹672 lakhs + ₹509 lakhs), pending shareholder approval via postal ballot, with proceeds earmarked for new ventures.
Despite improving top-line, widening losses and a swing to negative operating cash flow raise concerns about near-term financial health. However, the proposed monetisation of non-core assets at a substantial premium (~20x book value) could deliver a significant cash infusion and unlock shareholder value if shareholder approval is received by 31st January 2026.